Translational considerations for cancer nanomedicine

Journal of Controlled Release

Volumn 146, Issue 2, 2010, Pages 164-174

  Stern, Stephan T ^a   Hall, Jennifer B ^a   Yu, Lee L ^b   Wood, Laura J ^b   Paciotti, Giulio F ^c   Tamarkin, Lawrence ^c   Long, Stephen E ^b   McNeil, Scott E ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^c CytImmune Sciences Inc   (United States)

Author keywords

Allometry; Biological potency; Clinical starting dose; Modeling and simulation; Nanotechnology

Indexed keywords

BIOLOGY; DISEASES; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; NANOTECHNOLOGY;

ACTIVE PHARMACEUTICAL INGREDIENTS; ALLOMETRY; BIOLOGICAL POTENCY; CLINICAL STARTING DOSE; COMPLEX FORMULATIONS; MODEL AND SIMULATION; NANOTECHNOLOGY PRODUCTS; PRECLINICAL DEVELOPMENT;

BIOINFORMATICS;

AURIMUNE; CERAMIDE; FOLATE RECEPTOR; GOLD NANOPARTICLE; GREEN FLUORESCENT PROTEIN; INSULIN; LIPOSOME; PACLITAXEL; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLOMETRY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; BIOLOGICAL THERAPY; CANCER THERAPY; CASE REPORT; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DISTRIBUTION VOLUME; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG RETENTION; ENCAPSULATION; FEMALE; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MALE; MAXIMUM TOLERATED DOSE; NANOMEDICINE; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; TOXICITY TESTING;

EID: 77955430484     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.04.008     Document Type: Article

References (61)

1. McNeil S.E. Nanotechnology for the biologist. J. Leukoc. Biol. 2005, 78:585-594.
2. Sandanaraj B.S., Gremlich H.U., Kneuer R., Dawson J., Wacha S. Fluorescent nanoprobes as a biomarker for increased vascular permeability: implications in diagnosis and treatment of cancer and inflammation. Bioconjugate Chem. 2010, 21:93-101.
3. Akiyama Y., Mori T., Katayama Y., Niidome T. The effects of PEG grafting level and injection dose on gold nanorod biodistribution in tumor-bearing mice. J. Control. Release 2009, 139:81-84.
4. Thomas T.P., Ye J.Y., Chang Y.C., Kotlyar A., Cao Z., Majoros I.J., Norris T.B., Baker J.R. Investigation of tumor cell targeting of a dendrimer nanoparticle using a double-clad optical fiber probe. J. Biomed. Opt. 2008, 13:014024.
5. Hussain S., Pluckthun A., Allen T.M., Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther. 2007, 6:3019-3027.
6. Niihara R., Balakrishnan K. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine 2006, 2:127-136.
7. Zolnik B.S., Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv. Drug Deliv. Rev. 2009, 61:422-427.
8. Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med. 2010, 267:89-105.
9. Patri A.K., Dobrovolskaia M.A., Stern S.T., McNeil S.E. Preclinical characterization of engineered nanoparticles intended for cancer therapeutics. Nanotechnology for Cancer Therapy 2006, 105-138. CRC Press, Boca Raton, Florida. M. Amiji (Ed.).
10. National Research Council Guide for Care and Use of Laboratory Animals 1996, National Academy Press, Washington, D.C.
11. FDA, ICH, Guidance for Industry, S9 Nonclinical Evaluation for Anticancer Pharmaceuticals. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Rockville, MD, February, 2009.
12. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M., Sausville E.A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 2001, 84:1424-1431.
13. Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol. Appl. Pharmacol. 2008, 229:121-134.
14. Levin A.A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta. 1999, 1489:69-84.
15. FDA, ICH, Guidance for Industry, S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Rockville, MD, July 1997.
16. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil SE S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 2008, 5:487-495.
17. Winkler G.C. Pulmonary intravascular macrophages in domestic animal species: review of structural and functional properties. Am. J. Anat. 1988, 181:217-234.
18. Brain J.D., Molina R.M., DeCamp M.M., Warner A.E. Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species. Am. J. Physiol. 1999, 276:L146-L154.
19. FDA, Guidance for Industry, Single Dose Acute Toxicity Testing for Pharmaceuticals, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, August, 1996.
20. S.C. Gad, Testing guidelines and subchronic and chronic toxicity studies, In Drug Safety Evaluation (S.C. Gad Ed.), 1st ed., pp. 56-59 and 241-243. John Wiley & Sons, New York (2002).
21. ICH Harmonised tripartite guideline, guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2), Current Step 4 version, June 11 2009.
22. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.I., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
23. Cho M., Cho W.S., Choi M., Kim S.J., Han B.S., Kim S.H., Kim H.O., Sheen Y.Y., Jeong J. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol. Lett. 2009, 189:177-183.
24. Liu D., Mori A., Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim. Biophys. Acta. 1992, 1104:95-101.
25. Borchardt G., Brandriss S., Kreuter J., Margel S. Body distribution of 75Se-radiolabeled silica nanoparticles covalently coated with omega-functionalized surfactants after intravenous injection in rats. J. Drug Target 1994, 2:61-77.
26. FDA. Guidance for Industry, Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Rockville, MD, June 2004.
27. DeGeorge J.J., Ahn C.H., Andrews P.A., Brower M.E., Giorgio D.W., Goheer M.A., Lee-Ham D.Y., McGuinn W.D., Schmidt W., Sun C.J., Tripathi S.C. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother. Pharmacol. 1998, 41:173-185.
28. Manil L., Couvreur P., Mahieu P. Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles. Pharm. Res. 1995, 12:85-87.
29. Charrois G.J., Allen T.M. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim. Biophys. Acta. 2003, 1609:102-108.
30. FDA, Guidance for Industry, Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, August 2002.
31. ASTM F750-87 Standard Practice for Evaluating Material Extracts by Systemic Injection in the Mouse, 2002.
32. ASTM F619-03 Standard Practice for Extraction of Medical Plastics, 2008.
33. FDA, ICH, Guideline for Industry Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, March 1995.
34. Trethewey J. Bio-assays for the analysis of insulin. J. Pharm. Biomed. Anal. 1989, 7:189-197.
35. FDA, Guidance for Industry Potency Tests for Cellular and Gene Therapy Products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Rockville, MD, October 2008.
36. Myc A., Douce T.B., Ahuja N., Kotlyar A., Kukowska-Latallo J., Thomas T.P., Baker J.R. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates. Anticancer Drugs 2008, 19:143-149.
37. Bae Y., Nishiyama N., Fukushima S., Koyama H., Yasuhiro M., Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 2005, 16:122-130.
38. Purushotham S., Ramanujan R.V. Thermoresponsive magnetic composite nanomaterials for multimodal cancer therapy. Acta Biomater. 2010, 6(no. 2):502-510.
39. Zolnik B.S., Stern S.T., Kaiser J.M., Heakal Y., Clogston J.D., Kester M., McNeil S.E. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab. Dispos. 2008, 36(no. 8):1709-1715.
40. Weiss H.M., Fresneau M., Camenisch G.P., Kretz O., Gross G. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Drug Metab. Dispos. 2006, 34:971-975.
41. Harashima H., Iida S., Urakami Y., Tsuchihashi M., Kiwada H. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. J. Control. Release 1999, 61:93-106.
42. FDA, Guidance for Industry, Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Rockville, MD, March 2008.
43. Gardner E.R., Dahut W., Figg W.D. Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2008, 862:213-218.
44. Sonnichsen D.S., Relling M.V. Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 1994, 27:256-269.
45. Zamboni W.C., Strychor S., Joseph E., Walsh D.R., Zamboni B.A., Parise R.A., Tonda M.E., Yu N.Y., Engbers C., Eiseman J.L. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin. Cancer. Res. 2007, 13:7217-7223.
46. Zhao X., Mou D., Wan J., Xu H., Yang X. A novel method for the separation and determination of non-encapsulated pyrene in plasma and its application in pharmacokinetic studies of pyrene-loaded MPEG-PLA based nanoparticles. Nanotechnology 2009, 20:12570.
47. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. 1966, 50(no. 4):219-244.
48. Travis C.C., White R.K. Interspecific scaling of toxicity data. Risk Anal. 1988, 8:119-125.
49. FDA, Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, July 2005.
50. Mahmood I. Interspecies scaling of maximum tolerated dose of anticancer drugs: relevance to starting dose for phase I clinical trials. Am. J. Ther. 2001, 8:109-116.
51. Watanabe K., Bois F.Y., Zeise L. Interspecies extrapolation: a reexamination of acute toxicity data. Risk Anal. 1992, 12:301-310.
52. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J. Pharm. Sci. 2004, 93:177-185.
53. Mahmood I. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J. Pharm. Sci. 2009, 98(no. 10):3850-3861.
54. Baxter L.T., Zhu H., Mackensen D.G., Butler W.F., Jain R.K. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995, 55:4611-4622.
55. Davda J.P., Jain M., Batra S.K., Gwilt P.R., Robinson D.H. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int. Immunopharmacol. 2008, 8:401-413.
56. Luttringer O., Theil F.P., Poulin P., Schmitt-Hoffmann A.H., Guentert T.W., Lavé T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J. Pharm. Sci. 2003, 92:1990-2007.
57. Heiskanen T., Kairemo K. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. Curr. Pharm. Des. 2009, 15:988-1007.
58. Parrott N., Jones J.H., Paquereau N., Lavé T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin. Pharmacol. Toxicol. 2005, 96:193-199.
59. Liao C.M., Chiang Y.H., Chio C.P. Model-based assessment for human inhalation exposure risk to airborne nano/fine titanium dioxide particles. Sci. Total. Environ. 2008, 407:165-177.
60. Liao C.M., Chiang Y.H., Chio C.P. Assessing the airborne titanium dioxide nanoparticle-related exposure hazard at workplace. J. Hazard Mater. 2009, 162:57-65.
61. Shelley M.L., Wagner A.J., Hussain S.M., Bleckmann C. Modeling the in vivo case with in vitro nanotoxicity data. Int. J. Toxicol. 2008, 27:359-367.